This article explores the critical shift from simple drug administration to advanced long-acting delivery systems, detailing how innovations like nanotechnology and implantables are extending therapeutic windows and enhancing patient adherence across the biopharma landscape.
This article analyzes the FDA’s landmark accelerated approval of ELEVIDYS for Duchenne muscular dystrophy, highlighting how the patient’s voice, the use of surrogate biomarkers, and the management of “messy” data are reshaping the future path for cell and gene therapy approvals.
This article presents a framework for biopharma leaders to align corporate strategy with R&D and business development by evaluating disease areas across a lifecycle curve (Innovative, Growing, Mature) and assessing target validation to manage risk and drive high-value portfolio decisions.